FDA Approves Treatment for AML Patients With Gene Mutation

THURSDAY, Nov. 29, 2018 -- Xospata (gilteritinib) tablets were approved today by the U.S. Food and Drug Administration for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an FLT3 mutation, the agency announced in a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news